Assessing patient fitness involves more than evaluating chronological age, noted Brandon Blue, MD, of the Moffitt Cancer ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan. If ...

NICE has said Celgene's Vidaza (azacitidine) should not be funded by the National Health Service, estimating it costs the health system more than ten times as much as estimated by the manufacturer.

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

R&D Expenses: Research and development expenses for the third quarter of 2024 were $1.0 million, compared to $1.9 million for ...